Ján Kasper, PhD., MBA, PhD., Co-Founder & Managing Partner @ZAKA.VC

Co-Founder & Managing Partner @ZAKA.VC

  • ZAKA VC
  • Venture Capital & Private Equity
Rank
#1,371of 20,024
  • 22.8K followers
  • 19 posts / 60d
  • 0.5% avg engagement
  • 2.4K follower growth / 30d

Ján Kasper, PhD., MBA, PhD. ranks #1,371 of 20,024 creators on the LinkedIn Ranking, working in Venture Capital & Private Equity. They have 22.8K followers and published 19 posts in the last 60 days at a 0.5% average engagement rate.

The roast

Ján has two PhDs, an MBA, and over 50 companies, yet he spends his days begging for a 0.6% engagement rate on LinkedIn. It’s comforting to know that no matter how many degrees you collect, you can still graduate to being a digital panhandler.

About Ján

As the Co-Founder and Managing Partner at ZAKA VC, I manage a €17M venture capital Fund 1,vintage 2024We invest in early-stage startups with a global mindset, primarily in the healthcare, biotech, and industrial tech sectors. Our portfolio of Fund 1 currently includes 61 companies across the USA and Europe. My entrepreneurial journey began in 1988. I have built 70+ profitable companies and 20+ of them successfully sold. I have established myself as an experienced manager in various markets. From the year 2020 I have started to invest in startups. Since then I have been focusing on it full-time. First ,35 investments ,I did in family office, and then as an angel investor another 8. From the year 2024, I have been investing via Zaka Fund 1. My academic credentials include a technical diploma from the Slovak University of Technology, an MBA from Webster University in Vienna, and not one, but two PhDs — in Marketing from the University of Economics in Bratislava, and in Management from Comenius University. Aside from my professional endeavours, I was part of the original team that brought the Bratislava Jazz Days festival to life in 1974 — a cultural staple that continues to thrive. Though my marathon running days are over, my enthusiasm for sports remains undiminished, as I'm an ardent fan of both the NBA and the Champions League. I also take great pleasure in exploring the world of fine red wines. At the heart of my world are 4 remarkable women — my dear wife Alexandra and our three daughters: Valentina, Karolina, and Alexandra Jr., complemented by our son, Jan Jr. I speak 4 languages, studied at 4 universities, and ran 4 marathons. There are 4 countries I reside in – predominantly in Italy, with regular stays in Spain, the Czech Republic, and Slovakia. And so it seems, the number 4 not only signifies the pillars of my life but also appears to be my lucky char

Highlights

  • Top 10% in Venture Capital & Private Equity

    : Ranked #25 of 330 creators

  • Top 10% Audience

    : 22,808 followers

  • Top 25% Creator

    : 19 posts in 30 days

  • Top 25% Impact

    : 105 avg engagements per post

Recent posts

  • By the National Kidney Foundation's count, there are 931 gene therapies approved, in trials or awaiting approval worldwide. The number of them for kidney disease is zero. Not because the genetics are a mystery. Because the kidney's filtration barrier keeps the delivery vehicles out. That is the wall Nephrogen, a ZAKA VC portfolio company, has spent three years building a way through, and this month the National Kidney Foundation backed it. Its Innovation Fund has invested to advance a one-time gene editing therapy for polycystic kidney disease, the most common inherited kidney disease. Neph

    25 reactions · 0 comments · 0 reposts

  • AI can design a new molecule in seconds. Making it still takes a chemist several weeks. That gap is where most AI-designed molecules quietly die. b12 Labs (YC S25), a ZAKA VC portfolio company, just launched b12 Foundry to close it. You send a molecule that exists only on a screen. Their AI agents plan the synthesis, design the experiments and run them on robots in their partner lab at the University of Zurich. Back comes the compound in a vial, plus every result, failed reactions included. When I first wrote about b12, they were a chemistry copilot fresh out of Y Combinators Summer 2025 bat

    55 reactions · 4 comments · 0 reposts

  • Modern biology does not have a data problem. It has an understanding problem. A single mass spectrometry run produces more than most labs can analyse, and public archives hold years of it nobody has reopened. Tesorai, from our portfolio, is built for that gap: Search processes raw mass spectrometry data at scale, Chat lets a researcher interrogate results in plain English, and Trove brings in curated public datasets so a finding can be tested across studies. By their own benchmarks, 2,500 files now take under five hours instead of more than eight weeks. When JAMA Neurology published a blood

    46 reactions · 11 comments · 0 reposts

Last updated 2026-10-23